If you read the WHO document above, you will note the limitations of drugs that target a sole cytokine, suck as IL-6
an extract
The prospective and living network meta-analyses showed that in severely or critically ill patients, administering these drugs reduce the odds of death by 13%, compared to standard care. This means that there will be 15 fewer deaths per thousand patients, and as many as 28 fewer deaths for every thousand critically ill patients. The odds of mechanical ventilation among severe and critical patients are reduced by 28%, compared with standard care. This translates to 23 fewer patients out of a thousand needing mechanical ventilation.
If BIT225 can replicate in humans what it achieved in ACE2 mice, then there will be only one drug on everybody's lips (and in their gut).
The interesting thing is that we will know quite soon, relatively speaking, At least any interim results, The next Q is going to be very insightful.
Do you recall at the beginning of the pandemic how it was often said that vaccines 'take 10 years' to develop............. yet came about in one.
BIT225 only has to have one human trial, which it can go staright into because of its high safety profile.
What do you think the FDA is doing now with this recent Covid in vivo mouse and culture data for Delta from Biotron, with all its HIV safety data, not to mention the relationship between HIV and C-19 viroporin activity?
They won't be putting it in the bottom draw and saying, maybe one day. They will be analyzing it al pronto.
I believe we are going to hear about the commencement of huiman trials in the very, very near future.
Don't invest more than you are prepared to lose, and don't listen to bats, as it might be a conspiracy considering SARS2 originated with them.
Expand
